AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$TEVA

Satchi-Fainaro Ronit sold $15K of TEVA

Satchi-Fainaro Ronit sold 415 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $37.25 on 2026-08-21.

Original reporting
SEC EDGAR · Satchi-Fainaro Ronit
Published Aug 25, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEVA
Neutral
high confidence
Mentioned
$TEVA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to affect TEVA's stock price.

02

Market read

Minor insider transaction with limited trading relevance.

03

What to watch

The sale is under a 10b5-1 plan? It is not, indicating discretionary timing.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions; traders monitor for signals.

Company-level read

Ticker impact

$TEVANeutralHigh confidence
Context

Director Ronit Satchi-Fainaro sold 415 shares of TEVA for $15,458.75 on 2026-08-21.

Expected impact

No significant impact; price may stay flat.

Evidence & confidence

The transaction size is small relative to total holdings and market cap; typical for routine liquidity.

Market effects

Sector

None; insider sale does not affect pharma sector.

Regional

None; limited to TEVA shareholders.

Global

Low; no broader market effect.

Counterpoint

What could challenge this read

If the director anticipates near-term weakness, a small sell could hint at upcoming downside.

Key entities

  • Director
    Ronit Satchi-Fainaro

    Director at TEVA who sold shares.

  • Company
    TEVA PHARMACEUTICAL INDUSTRIES LTD

    Global pharmaceutical company listed on NYSE.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min
SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min